Cadrenal Therapeutics Stock (NASDAQ:CVKD)
Previous Close
$16.32
52W Range
$5.40 - $32.55
50D Avg
$13.95
200D Avg
$9.49
Market Cap
$25.10M
Avg Vol (3M)
$61.12K
Beta
-
Div Yield
-
CVKD Company Profile
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.